Ameriprise
CLDX icon

Ameriprise’s Celldex Therapeutics CLDX Stock Holding History

Ameriprise’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
+5,579
New +$180K ﹤0.01% 3954
2025
Q1 		– Sell
-9,944
Closed -$251K – 4039
2024
Q4 		$251K Buy
+9,944
New +$270K ﹤0.01% 3784
2018
Q2 		– Sell
-512,961
Closed -$17.9M – 3645
2018
Q1 		$17.9M Buy
512,961
+479,589
+1,437% +$18.6M 0.01% 1203
2017
Q4 		$1.42M Buy
33,372
+3,945
+13% +$169K ﹤0.01% 2834
2017
Q3 		$1.26M Buy
29,427
+3,975
+16% +$149K ﹤0.01% 2859
2017
Q2 		$943K Buy
+25,452
New +$1.13M ﹤0.01% 2970
2016
Q1 		– Sell
-16,185
Closed -$3.81M – 3766
2015
Q4 		$3.81M Buy
16,185
+1,538
+11% +$335K ﹤0.01% 2219
2015
Q3 		$2.32M Sell
14,647
-5,837
-28% -$1.65M ﹤0.01% 2535
2015
Q2 		$7.75M Buy
20,484
+4,213
+26% +$1.67M ﹤0.01% 1803
2015
Q1 		$6.8M Buy
16,271
+10,581
+186% +$3.79M ﹤0.01% 1889
2014
Q4 		$1.56M Buy
5,690
+2,576
+83% +$640K ﹤0.01% 2664
2014
Q3 		$605K Sell
3,114
-761
-20% -$166K ﹤0.01% 2982
2014
Q2 		$948K Sell
3,875
-19,844
-84% -$4.48M ﹤0.01% 2793
2014
Q1 		$6.29M Sell
23,719
-14,543
-38% -$5.57M ﹤0.01% 1867
2013
Q4 		$13.9M Buy
38,262
+11,938
+45% +$4.6M 0.01% 1262
2013
Q3 		$14M Buy
26,324
+21,108
+405% +$7.24M 0.01% 1236
2013
Q2 		$1.22M Buy
+5,216
New +$1.03M ﹤0.01% 2546

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's CLDX Position: Q2 2026 in Review

Ameriprise opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 5,579 shares worth $208K. The stake represents ﹤0.01% of the portfolio and ranks #3954 among its holdings. This is a return to the name: Ameriprise previously reported a position in CLDX as recently as Q4 2024.

Ameriprise first reported a position in CLDX in Q2 2013 and has held it in 17 quarters since. The position peaked at $17.9M in Q1 2018. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Ameriprise held 5,579 shares of Celldex Therapeutics worth $208K as of Q2 2026.
  • Celldex Therapeutics was a new Ameriprise position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3954 holding.
  • Ameriprise first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 17 quarters since.
  • Ameriprise's Celldex Therapeutics position peaked at $17.9M in Q1 2018.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.